iiinova — where your digital self keeps evolving

A new review explores the latest research on the complex tumour microenvironment of pituitary tumours (PiTs), examining how interactions between immune, stromal and vascular components shape tumour behaviour and treatment resistance. Read the review: doi.org/10.1530/ERC-...

000

A new review summarises the diagnostic workup required to differentiate arginine vasopressin (AVP) deficiency from AVP resistance and primary polydipsia, describes the various causes of AVP deficiency & discusses etiology-specific investigations. 🔗 doi.org/10.1530/ERC-26-0090

Pituitary Tumours: Scientific Discoveries, Clinical Advances and Contested Paradigms Special Collection
NEW REVIEW
Arginine vasopressin deficiency: towards a better characterization. Cihan Atila, Clara Consoli, Mirjam Christ-Crain
[Endocrine-Related Cancer]

000

New guidance now available on the reporting and subsequent clinical surveillance and management of patients with incidentally discovered RET gene variants in the UK. Read the expert consensus: doi.org/10.1530/ERC-...

000

New research in the World Congress on Thyroid Cancer 2025 Special Collection investigates the possible immune mechanisms underlying the association between lymphocytic thyroiditis and less aggressive papillary thyroid cancer. 🔗 doi.org/10.1530/ERC-26-0088

000

We are delighted to welcome Dr Mauro Cives and Prof. Longfei Liu to the Endocrine-Related Cancer Editorial Board as Associate Editors. Their extensive expertise across endocrine cancer research will be a valuable addition to our Editorial Board. Please join us in welcoming them!

000

A new review by Madson Q. Almeida, Patricia L. M. Dahia, and Mercedes Robledo summarizes advances in PPGL genomics, including geographic and sex-related particularities. 🔗 doi.org/10.1530/ERC-26-0258

000

A new review examines evidence on succinate dehydrogenase (SDH) germline mutation carriers, exploring the inheritance and penetrance of SDHx pathogenic variants, cellular adaptations linked to haploinsufficiency, and environmental influences on disease onset. 🔗 doi.org/10.1530/ERC-26-0282

001

A new review examines the current management of aggressive PitNETs, highlighting evidence gaps, emerging molecular insights, and several priorities that should shape the future research agenda. 🔗 doi.org/10.1530/ERC-25-0502 This paper forms part of the WorldMEN 2025 Special Collection.

000

A new study by Emma Boehm et al. explores the highly variable responses to PRRT in pancreatic neuroendocrine tumours (PNETs). Using whole genome or exome sequencing of 40 PNET samples, the study examines the genomic features associated with PRRT response. 🔗 doi.org/10.1530/ERC-26-0207

000

Peptide receptor radionuclide therapy (PRRT) is a promising targeted treatment for aggressive pituitary neuroendocrine tumours (PitNETs). Francesco Ferraù et al. review current evidence on the efficacy and safety of PRRT in this setting. 🔗Read the review: doi.org/10.1530/ERC-26-0109

000

A new review by Yair Schwarz, Reut Halperin and Amit Tirosh examines the significant progress in the molecular characterization of PitNETs, which has advanced understanding of the molecular pathways driving tumour initiation and progression. 🔗 Read the review: doi.org/10.1530/ERC-26-0213

000

What impact does ageing have on parathyroid disease? A new review explores parathyroid adenoma and carcinoma in older adults, highlighting evidence gaps and the need for larger studies to improve patient care. Read the review: doi.org/10.1530/ERC-26-0203

000

New Associate Editor joins our Editorial Board We are delighted to welcome Professor Svenja Nölting, an internationally recognised expert in pheochromocytomas, paragangliomas and neuroendocrine tumours, to the Endocrine-Related Cancer Editorial Board as an Associate Editor.

010

Can AI improve decision-making across the pituitary patient pathway? A new review by George Hudson et al. examines the latest advances in AI algorithms and the potential applications of AI across pre-, intra- and post-operative stages of pituitary care. #OpenAccess 🔗 doi.org/10.1530/ERC-26-0104

000

What are the metabolic determinants underlying lineage-specific characteristics in pituitary neuroendocrine tumors (PitNETs)? A new study demonstrates that TF-defined PitNET lineages exhibit distinct intratumoral steroid metabolite profiles. 🔗 doi.org/10.1530/ERC-26-0154

000

We are delighted to welcome Assistant Prof. Jung Hee Kim to the Endocrine-Related Cancer Editorial Board as an Associate Editor. A leading expert in pituitary and adrenal tumours, Jung's appointment further strengthens our editorial expertise in these important areas of endocrine cancer research.

000

In a new review, Stephen Ludgate et al. examine the current state and future directions of functional imaging approaches across major hereditary syndromes, including MEN types 1–4, von Hippel–Lindau disease & hereditary paraganglioma–phaeochromocytoma syndromes. 🔗 doi.org/10.1530/ERC-25-0516

011

Endocrine-Related Cancer is seeking a Deputy Editor to join its expert Editorial Board. This is an opportunity to help shape the journal’s direction & contribute to advancing research in the field of endocrine oncology. Learn more: journals.bioscientifica.com/erc/pages/vacancies

000

In a new retrospective cohort study, hormone-secreting lung-NENs were associated with shorter overall survival than non-secreting lung-NENs, with multiple hormone secretion identified as an independent negative prognostic factor. 🔗 Read the full research #OpenAccess: doi.org/10.1530/ERC-26-0142

001

Emerging Leader Spotlight: Dr Rayzel Fernandes @imperialcollegeldn.bsky.social A 2026 Endocrine-Related Cancer Emerging Leader, Dr Fernandes' latest review examines factors driving AR cistrome reprogramming in prostate cancer progression & its potential clinical utility. 🔗 doi.org/10.1530/ERC-...

000

New research by Malin Hagberg Thulin et al. highlights the critical role of adrenal-dependent androgen synthesis in driving the sclerotic castration-resistant prostate cancer (CRPC) within the bone microenvironment. Read the research: doi.org/10.1530/ERC-...

000

Reposted by Endocrine-Related Cancer

Bence Kövér @bencekover.bsky.social · 30/06/2026

Happy to see our new review paper led by @jameskcl.bsky.social . We discuss evidence on the role of stem cells in pituitary tumours. Furthermore, we discuss practical criteria for identifying stem cells, and develop a framework for their possible contributions to tumours. @pituitarylab.bsky.social

022

🧠 What role do stem cells play in pituitary tumour formation and progression? A new review examines the current evidence implicating pituitary stem cells and tumour stem-like populations in pituitary tumour biology. 🔗 Read the review: doi.org/10.1530/ERC-26-0171

010

We’re pleased to spotlight Johannes Hofland, an Endocrine-Related Cancer Emerging Leader, & co-author on: Gut microbial and functional alterations lead to metagenomic signatures for midgut neuroendocrine tumor patients and for carcinoid syndrome 🔗 Read the article: doi.org/10.1530/ERC-24-0145

121

New research by Yasmine Kemkem et al. provides the first functional evidence suggesting that SOX2+ cells in phaeochromocytomas (PCCs) and paragangliomas (PGLs), collectively known as PPGLs, possess the potential to serve as tumour cells of origin. Read the full research: doi.org/10.1530/ERC-...

010

We’re pleased to spotlight Katherine Wolf, an Endocrine-Related Cancer Emerging Leader, and author on a new paper exploring an important question: could adrenocortical carcinoma (ACC) be associated with Birt–Hogg–Dubé syndrome (BHDS)? 🔗 Read the article: doi.org/10.1530/ERC-...

000

How do EVs from obese adipose tissue drive malignancy in breast cancer? New research investigates the effects of obese AT-derived EVs on MCF‑7 cells by analysing the changes in cellular functions, epithelial marker expression, and signaling pathways. 🔗 doi.org/10.1530/ERC-...

100

A new review by K. Mansukhbhai Shekhda et al. evaluates the effects of NET therapies, including somatostatin analogues, molecular targeted therapy, peptide receptor radionuclide therapy and chemotherapy, on reproductive and sexual function in patients with NETs. 🔗 doi.org/10.1530/ERC-25-0500

000

In a new review, Borbála Szabó, Attila Patocs & Henriett Butz examine DNA methylation–demethylation cycle in PitNETs, highlight challenges of detecting cytosine modifications & outline emerging evidence linking altered demethylation to tumour biology. 🔗 doi.org/10.1530/ERC-26-0030

000

A new mini review by Mia Zol‑Hanlon and Neil Q. McDonald explores progress in defining RET receptor architecture & discusses current models for how distinct assemblies of GFL–GFRα–RET receptor complexes activate intrinsic RET tyrosine kinase to relay signals. 🔗 doi.org/10.1530/ERC-25-0322

000

🎉 Congratulations to Associate Professor Matti Gild, winner of the Emerging Leader Best Paper Award 2025 for her outstanding contribution to the field with the paper: “Evaluating the prognostic potential of circulating cell‑free DNA in advanced thyroid cancer” 🔗 doi.org/10.1530/ERC-24-0227

010

Reposted by Endocrine-Related Cancer

Bence Kövér @bencekover.bsky.social · 29/04/2026

Amongst the many cool things, we: - characterised SOX2+ expressing cells across PPGLs - identified expression signatures associated with metastatic potential - identified changes in expression between SOX2+ high versus SOX2+ low samples The paper is now out in @endocancer.bsky.social

011

Reposted by Endocrine-Related Cancer

Bence Kövér @bencekover.bsky.social · 29/04/2026

I’m really glad to have been a part of this exciting project studying rare neuroendocrine tumours called phaeochromocytomas and paragangliomas. We performed 10x Genomics single-cell/nucleus RNA-seq on 7 PPGL patients, and integrated published data from another 12 patients. doi.org/10.1530/ERC-...

doi.org

121

New research by Akitada Yogo et al. characterises microscopic small‑intestinal neuroendocrine tumorlets (SINTs) found in multifocal SI‑NETs, assessing their clinicopathological features and possible roles in multifocal tumorigenesis. 🔗 Read the research: doi.org/10.1530/ERC-25-0425

000

The WorldMEN 2025 Special Collection is inviting complementary papers from researchers who weren't able to attend the event but whose work meaningfully contributes to understanding the unmet needs in multiple endocrine neoplasia syndromes. Learn more: erc.bioscientifica.com/page/WorldMEN-2025

000

A new review by Virginia Corbett, Garima Gupta, and Aman Chauhan synthesises recent clinical trials, cohort studies, and expert consensus to clarify the role of peptide receptor radionuclide therapy in neuroendocrine tumours management. Read the review #OpenAccess: doi.org/10.1530/ERC-...

000

Pituitary neuroendocrine tumours (PitNETs) in elderly people (≥65 years) is increasing as life expectancy rises. A new review examines the biology & clinical features of PitNETs in elderly people to support further research in this patient population. 🔗 doi.org/10.1530/ERC-25-0535

000

New research by Nilakshi Kulathunga et al. investigates whether the avian chorioallantoic membrane can support engraftment of tumour fragments from well‑differentiated NETs. 🔗Read the research #OpenAccess: doi.org/10.1530/ERC-25-0377

000

Giant cell tumours rarely occur in the skull. A new review summarises current understanding about these cases, reporting 79 sphenoid GCTs & adding 2 new cases. This article forms part of our Emerging Leader Collection, featuring rising researcher Fanny Chasseloup 👏 🔗 doi.org/10.1530/ERC-24-0289

000

A new study by Qianjin Guo et al. leveraged human SDHB-deficient UOK269 RCC cells (SDHB-KO) and isogenic SDHB-reconstituted control cells (SDHB-WT) to identify intrinsic susceptibilities of SDHB-deficient cancers that could be therapeutically leveraged. Read the article: doi.org/10.1530/ERC-25-0397

000

Alisson Clemenceau et al. synthesises over 3 decades of human observational studies, using systematic review & meta‑analyses to examine how PTHrP relates to prognostic tumour characteristics & patient outcomes in women with breast cancer. Read the full study #OpenAccess: doi.org/10.1530/ERC-25-0324

010

🆕 NANETS Guidelines for the diagnosis and management of stage I–III rectal neuroendocrine tumors 🔗 doi.org/10.1530/ERC-25-0303

000

Reposted by Endocrine-Related Cancer

University of Illinois Cancer Center @uicancercenter.bsky.social · 26/02/2026

Can GLP-1 receptor agonists, used to treat diabetes and obesity, play a role in #ProstateCancer? A new study from University of Illinois Chicago researchers, published in @endocancer.bsky.social, explores the link. Read more: bit.ly/4kRIonU

011

What is the clinical relevancy of germline & somatic SDHA pathogenic/likely pathogenic (P/LP) variants in cancer patients? A recent comprehensive analysis by Henriett Butz et al. investigates prevalence & clinical relevance of germline & somatic SDHA P/LP variants. doi.org/10.1530/ERC-25-0281

000

Jonathan R Strosberg et al. publish a subgroup analysis of the phase 3 CABINET trial, evaluating outcomes in patients with well-differentiated grade 3 neuroendocrine tumours (G3 NETs; Ki-67 > 20%). Read the article: doi.org/10.1530/ERC-25-0415

000

Call for Papers: The Biology of Aging and Endocrine‑Related Cancers This collection aims to improve understanding of how aging biology influences endocrine‑related cancer risk, treatment responses, and patient outcomes. For more info visit: erc.bioscientifica.com/page/Biology-of-Aging

000

How does ageing shape adrenal tumours? A new mini-review by Abel Decmann et al. summarises how age‑related changes in the adrenal cortex and medulla, from structural remodelling to shifts in immune & cellular balance, may influence tumorigenesis. Read the article: doi.org/10.1530/ERC-25-0150

000

Marking 30 years, the RET@Thirty Special Collection features an exclusive editorial with Professor Sir Bruce Ponder & brings together mini-reviews addressing the multifaceted aspects of RET & its impact on clinical practice. Explore the collection: erc.bioscientifica.com/page/RET@Thirty

Endocrine-Related Cancer.

RET@Thirty: Three Decades of Remarkable Progress.
Special Collection.

021

Could AIP loss-of-function contribute to neuroendocrine neoplasms (NENs) beyond pituitary tumours? Blanca R Carranza-Zavala et al. investigated the prevalence and in‑vitro effects of germline AIP variants in Mexican patients with NENs. 🔓 Full research #OpenAccess: doi.org/10.1530/ERC-25-0095

000

A new study by Marijn L van den Berg et al. analyses long‑term calcitonin trends in 52 MEN2A patients after total thyroidectomy, revealing distinct postoperative patterns that could inform more personalised surveillance. 🔓 Read the full article: doi.org/10.1530/ERC-25-0366

020